• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

作为热休克蛋白90(HSP90)抑制剂的C环截短鱼藤素衍生物的合成及生物学评价

Synthesis and biological evaluation of C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors.

作者信息

Kim Ho Shin, Hong Mannkyu, Ann Jihyae, Yoon Suyoung, Nguyen Cong-Truong, Lee Su-Chan, Lee Ho-Young, Suh Young-Ger, Seo Ji Hae, Choi Hoon, Kim Jun Yong, Kim Kyu-Won, Kim Joohwan, Kim Young-Myeong, Park So-Jung, Park Hyun-Ju, Lee Jeewoo

机构信息

Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.

SNU-Harvard NeuroVascular Protection Research Center, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.

出版信息

Bioorg Med Chem. 2016 Nov 15;24(22):6082-6093. doi: 10.1016/j.bmc.2016.09.067. Epub 2016 Sep 30.

DOI:10.1016/j.bmc.2016.09.067
PMID:27745993
Abstract

Based on the lead compound L-80 (compound 2), a potent heat shock protein 90 (HSP90) inhibitor, a series of C-ring truncated deguelin analogs were designed, synthesized and evaluated for Hypoxia Inducible Factor-1α (HIF-1α) inhibition as a primary screening method. Their structure-activity relationship was investigated in a systematic manner by varying the A/B ring, linker and D/E ring, respectively. Among the synthesized inhibitors, compound 5 exhibited potent HIF-1α inhibition in a dose-dependent manner and significant antitumor activity in human non-small cell lung carcinoma (H1299), with better activities than L-80. It also inhibited in vitro hypoxia-mediated angiogenic processes in human retinal microvascular endothelial cells (HRMEC). The docking study of 5 showed a similar binding mode as L-80: it occupied the C-terminal ATP-binding pocket of HSP90, indicating that the anticancer and antiangiogenic activities of 5 were derived from HIF-1α destabilization by inhibiting the C-terminal ATP-binding site of hHSP90.

摘要

基于先导化合物L-80(化合物2),一种有效的热休克蛋白90(HSP90)抑制剂,设计、合成了一系列C环截短的鱼藤素类似物,并将其对缺氧诱导因子-1α(HIF-1α)的抑制作用作为主要筛选方法进行评估。通过分别改变A/B环、连接子和D/E环,系统地研究了它们的构效关系。在合成的抑制剂中,化合物5以剂量依赖的方式表现出对HIF-1α的强效抑制作用,并在人非小细胞肺癌(H1299)中具有显著的抗肿瘤活性,活性优于L-80。它还能抑制人视网膜微血管内皮细胞(HRMEC)体外缺氧介导的血管生成过程。对化合物5的对接研究显示出与L-80相似的结合模式:它占据了HSP90的C端ATP结合口袋,表明化合物5的抗癌和抗血管生成活性源自通过抑制hHSP90的C端ATP结合位点使HIF-1α不稳定。

相似文献

1
Synthesis and biological evaluation of C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors.作为热休克蛋白90(HSP90)抑制剂的C环截短鱼藤素衍生物的合成及生物学评价
Bioorg Med Chem. 2016 Nov 15;24(22):6082-6093. doi: 10.1016/j.bmc.2016.09.067. Epub 2016 Sep 30.
2
Ring-truncated deguelin derivatives as potent Hypoxia Inducible Factor-1α (HIF-1α) inhibitors.环状截短的去甲斑蝥素衍生物作为有效的缺氧诱导因子-1α(HIF-1α)抑制剂。
Eur J Med Chem. 2015 Nov 2;104:157-64. doi: 10.1016/j.ejmech.2015.09.033. Epub 2015 Sep 30.
3
Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents.研究 B、C 环截断的去甲氧基格尔德霉素衍生物作为热休克蛋白 90(HSP90)抑制剂用于治疗乳腺癌。
Bioorg Med Chem. 2019 Apr 1;27(7):1370-1381. doi: 10.1016/j.bmc.2019.02.040. Epub 2019 Feb 20.
4
Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis.新型基于德古醇的热休克蛋白 90(HSP90)抑制剂的设计、合成及对增殖和血管生成的生物学评价。
J Med Chem. 2012 Dec 27;55(24):10863-84. doi: 10.1021/jm301488q. Epub 2012 Dec 7.
5
Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.新型地谷新衍生物L80的合成与评价,该衍生物可破坏ATP与热休克蛋白90 C末端结构域的结合
Mol Pharmacol. 2015 Aug;88(2):245-55. doi: 10.1124/mol.114.096883. Epub 2015 May 14.
6
Discovery of a simplified deguelin analog as an HSP90 C-terminal inhibitor for HER2-positive breast cancer.发现一种简化的鱼藤素类似物作为HER2阳性乳腺癌的HSP90 C端抑制剂。
Bioorg Med Chem Lett. 2021 Aug 1;45:128134. doi: 10.1016/j.bmcl.2021.128134. Epub 2021 May 24.
7
Structural basis for depletion of heat shock protein 90 client proteins by deguelin.鱼藤素导致热休克蛋白90客户蛋白耗竭的结构基础
J Natl Cancer Inst. 2007 Jun 20;99(12):949-61. doi: 10.1093/jnci/djm007. Epub 2007 Jun 12.
8
Design, synthesis, and biological evaluation of truncated deguelin derivatives as Hsp90 inhibitors.设计、合成及截短变形轮环藤素衍生物作为 Hsp90 抑制剂的生物学评价。
Eur J Med Chem. 2019 Apr 1;167:485-498. doi: 10.1016/j.ejmech.2019.02.014. Epub 2019 Feb 12.
9
Discovery of novel anti-breast cancer agents derived from deguelin as inhibitors of heat shock protein 90 (HSP90).发现源自鱼藤素的新型抗乳腺癌药物作为热休克蛋白90(HSP90)抑制剂。
Bioorg Med Chem Lett. 2020 Sep 1;30(17):127374. doi: 10.1016/j.bmcl.2020.127374. Epub 2020 Jul 2.
10
Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha.鱼藤素靶向缺氧诱导因子-1α的新型抗血管生成抗癌活性鉴定
Int J Cancer. 2008 Jan 1;122(1):5-14. doi: 10.1002/ijc.23075.

引用本文的文献

1
Deguelin's Anticancer Bioactivity: Challenges and Opportunities in Medicinal Chemistry.鱼藤素的抗癌生物活性:药物化学中的挑战与机遇
Front Pharmacol. 2025 Jun 26;16:1571452. doi: 10.3389/fphar.2025.1571452. eCollection 2025.
2
Heat shock proteins as hallmarks of cancer: insights from molecular mechanisms to therapeutic strategies.热休克蛋白作为癌症的标志:从分子机制到治疗策略的见解。
J Hematol Oncol. 2024 Sep 4;17(1):81. doi: 10.1186/s13045-024-01601-1.
3
A silicon-containing aryl/penta-1,4-dien-3-one/amine hybrid exhibits antiproliferative effects on breast cancer cells by targeting the HSP90 C-terminus without inducing heat-shock response.
一种含硅芳基/戊-1,4-二烯-3-酮/胺杂化物通过靶向热休克蛋白90(HSP90)的C末端对乳腺癌细胞发挥抗增殖作用,且不会诱导热休克反应。
RSC Med Chem. 2023 Oct 23;14(12):2625-2639. doi: 10.1039/d3md00431g. eCollection 2023 Dec 13.
4
Ligand-based pharmacophore modelling, structure optimisation, and biological evaluation for the identification of 2-heteroarylthio--arylacetamides as novel HSP90 C-terminal inhibitors.基于配体的药效团建模、结构优化及生物学评价,以鉴定2-杂芳硫基-芳基乙酰胺类化合物作为新型HSP90 C末端抑制剂。
J Enzyme Inhib Med Chem. 2024 Dec;39(1):2290912. doi: 10.1080/14756366.2023.2290912. Epub 2023 Dec 11.
5
Inhibitory Effects of B-, C-, and E-Ring-Truncated Deguelin Derivatives Against A549, HCT116, and MCF-7 Cancer Cells.B环、C环和E环截短的鱼藤素衍生物对A549、HCT116和MCF-7癌细胞的抑制作用。
ACS Omega. 2023 Nov 2;8(45):43109-43117. doi: 10.1021/acsomega.3c06619. eCollection 2023 Nov 14.
6
Recent advances toward the development of Hsp90 C-terminal inhibitors.近年来开发 Hsp90 C 端抑制剂的进展。
Bioorg Med Chem Lett. 2023 Jan 15;80:129111. doi: 10.1016/j.bmcl.2022.129111. Epub 2022 Dec 19.
7
The disruption of protein-protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition.破坏与共伴侣蛋白和客户底物的蛋白质-蛋白质相互作用作为一种抑制Hsp90的策略。
Acta Pharm Sin B. 2021 Jun;11(6):1446-1468. doi: 10.1016/j.apsb.2020.11.015. Epub 2020 Nov 24.
8
Development and Validation of Analytical Method for SH-1242 in the Rat and Mouse Plasma by Liquid Chromatography/Tandem Mass Spectrometry.SH-1242 在大鼠和小鼠血浆中的液相色谱/串联质谱分析方法的建立与验证。
Molecules. 2020 Jan 25;25(3):531. doi: 10.3390/molecules25030531.
9
Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer.新型 Hsp90 抑制剂 NCT-50 的开发作为治疗非小细胞肺癌的潜在抗癌药物。
Sci Rep. 2018 Sep 17;8(1):13924. doi: 10.1038/s41598-018-32196-6.